AMAG Pharmaceuticals, Inc. to Host Conference Call on May 3, 2011 at 4:30 p.m. ET to Discuss Financial Results for the Qua

LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2011 after the U.S. financial markets close on May 3, 2011. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will discuss the Company’s financial results, commercial progress and development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 7:30 p.m. ET on May 3, 2011 through midnight May 5, 2011. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The pass code for the live call and the replay is 57692403.

The call will be webcast with slides and accessible through the Investors section of the Company’s website at www.amagpharma.com. The webcast replay will be available from approximately 7:30 p.m. ET on May 3, 2011 through midnight June 3, 2011.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit www.amagpharma.com or http://feraheme.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.



CONTACT:

AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.